Your IP: 38.107.179.214 United States Near: United States

Lookup IP Information

1 2 3 4 5 6 7 8 Next

Below is the list of all allocated IP address in 44.119.0.0 - 44.119.255.255 network range, sorted by latency.

Garenoxacin Systematic (IUPAC) name 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Identifiers CAS number 91421-42-0 ATC code J01MA19 PubChem CID 124093 KEGG D04031 Y Chemical data Formula C23H20F2N2O4  Mol. mass 426.412 g/mol Therapeutic considerations Pregnancy cat.  ? Legal status  ? Routes Oral  Y(what is this?)  (verify) Garenoxacin (INN) is a quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections. It was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, and China. On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration has accepted the New Drug Application (NDA) for garenoxacin, and has been granted a 10-month review.[1] Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic Garenoxacin.[2] The European Medicines Agency (EMEA) had also been formally notified by Schering-Plough Europe (July 28 2007) of its decision to withdraw the application for a centralized marketing authorization for Garenoxacin as well. [3][4][5] Based on the CHMP review of the data regarding safety and efficacy, (risk/benefit) the CHMP considered the application for Garenoxacin to be unapprovable. [6] See also Fluoroquinolone toxicity Fluoroquinolone References ^ "Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review". http://www.drugs.com/nda/garenoxacin_060213.html. Retrieved 2008-03-25.  ^ http://www.fiercebiotech.com/story/schering-plough-pulls-its-garenoxacin-app/2006-08-21 ^ http://www.medicalnewstoday.com/articles/78052.php ^ http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/34117407en.pdf ^ http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf ^ http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf v · d · eAntibacterials: nucleic acid inhibitors (J01E, J01M) Antifolates (inhibits purine metabolism, thereby inhibiting DNA and RNA synthesis) DR inhibitor 2,4-Diaminopyrimidine (Trimethoprim#, Brodimoprim, Tetroxoprim, Iclaprim†) Sulfonamides (DS inhibitor) Short- acting Sulfaisodimidine • Sulfamethizole • Sulfadimidine • Sulfapyridine • Sulfafurazole • Sulfanilamide (Prontosil) • Sulfathiazole • Sulfathiourea Intermediate- acting Sulfamethoxazole • Sulfadiazine# • Sulfamoxole Long- acting Sulfadimethoxine • Sulfalene • Sulfametomidine • Sulfametoxydiazine • Sulfamethoxypyridazine • Sulfaperin • Sulfamerazine • Sulfaphenazole • Sulfamazone Other/ungrouped sulfanilamide (Sulfacetamide, Sulfametrole) Combinations Trimethoprim/sulfamethoxazole# Topoisomerase inhibitors/ quinolones/ (inhibits DNA replication) 1st g. Cinoxacin‡ • Flumequine • Nalidixic acid • Oxolinic acid • Pipemidic acid • Piromidic acid • Rosoxacin Fluoro- quinolones 2nd g. Ciprofloxacin#  • Enoxacin‡ • Fleroxacin‡ • Lomefloxacin • Nadifloxacin • Ofloxacin • Norfloxacin • Pefloxacin • Rufloxacin 3rd g. Balofloxacin • Grepafloxacin‡ • Levofloxacin • Pazufloxacin • Sparfloxacin‡ • Temafloxacin‡ • Tosufloxacin 4th g. Besifloxacin • Clinafloxacin† • Garenoxacin • Gemifloxacin • Moxifloxacin • Gatifloxacin‡ • Sitafloxacin • Trovafloxacin‡/Alatrofloxacin‡ • Prulifloxacin Vet. Danofloxacin • Difloxacin • Enrofloxacin • Ibafloxacin • Marbofloxacin • Orbifloxacin • Pradofloxacin • Sarafloxacin Related (DG) Aminocoumarins: Novobiocin Anaerobic DNA inhibitors Nitro- imidazole derivatives Metronidazole#  • Tinidazole • Ornidazole Nitrofuran derivatives Nitrofurantoin#  • Furazolidone‡  • Nifurtoinol RNA synthesis Rifamycins/ RNA polymerase Rifampicin • Rifabutin • Rifapentine • Rifaximin #WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III M: BAC bact (clas) gr+f/gr+a(t)/gr-p(c)/gr-o drug(J1p, w, n, m, vacc) This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.v · d · e